Feasibility study of dose eslation and concentration in stereotactic body radiotherapy (SBRT) for lung tumors
Phase 1
- Conditions
- T1-4N0M0 non-small cell lung cancer solitary or ipsilateral two lung metastasis
- Registration Number
- JPRN-UMIN000006172
- Lead Sponsor
- Ofuna SBRT study group
- Brief Summary
The median follow-up duration was 22.0 (12.0-27.0) months. After 6 months post-SBRT, the respective number of RP Grade 0, 1 and 2 cases was 5, 9 and 1. In the Grade 2 RP patient, the image showed an organizing pneumonia pattern at 6.0 months post-SBRT. No other toxicity was found. At last follow-up, there was no evidence of recurrence of the treated tumors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. apparent interstitial pneumonitis and fibrosis 2. active inflamation without oral drugs 3. double cancer 4. pregnancy 5. psychiatric disorder 6. steroid administration 7. oxygen administration 8. fever of 38.0 degrees centigrade or higher 9. narcotics administration for coughing
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence of Grade 2 or more radiation pneumonits within 180 days after stereotactic radiotherapy
- Secondary Outcome Measures
Name Time Method incidence of Grade 3 or more radiation pneumonitis, adverse events, severe adverse events, local progression free survival, 3-year local progression free survival, event free survival